Summary
DNA base lesions, such as incorporation of uracil into DNA or base mismatches, can be mutagenic and toxic to replicating cells. To discover factors in repair of genomic uracil, we performed a CRISPR knockout screen in the presence of floxuridine, a chemotherapeutic agent that incorporates uracil and fluoro-uracil into DNA. We identified known factors, such as uracil DNA N-glycosylase (UNG), and unknown factors, such as the N6-adenosine methyltransferase, METTL3, as required to overcome floxuridine-driven cytotoxicity. Visualized with immunofluorescence, the product of METTL3 activity, N6-methyladenosine, formed nuclear foci in cells treated with floxuridine. The observed N6-methyladenosine was embedded in DNA, called 6mA, and these results were confirmed using an orthogonal approach, liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). METTL3 and 6mA were required for repair of lesions driven by additional base damaging agents, including raltitrexed, gemcitabine, and hydroxyurea. Our results establish a role for METTL3 and 6mA in promoting genome stability in mammalian cells, especially in response to base damage.
Competing Interest Statement
B.A.C., L.N., D.T., S.V., T.J.M., C.N., P.S., Q.X., L.S., J.A., D.S. and M.O. are or were employees of Pfizer Inc. and may own Pfizer stock. P.P., R.T.V., N.D.L.C., and B.R.S., received research funding from Pfizer Inc. B.R.S. is an advisory board member of Molecular Cell.
Footnotes
↵6 Lead Contact: Mariano.oppikofer{at}gmail.com
This version of the manuscript has been revised to include updates in response to peer-review at eLife.
